HVTN 505 is being conducted to determine the safety and efficacy of a Vaccine Research Center DNA/rAd5 vaccine regimen in healthy males and male-to-female transgender persons who have sex with men [REF].
When the study began the primary outcome being measured was whether the vaccine decreased the viral load, which is amount of HIV in the blood of study participants who received the vaccine then later became infected with HIV.